<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404635</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-562</org_study_id>
    <nct_id>NCT03404635</nct_id>
  </id_info>
  <brief_title>Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism</brief_title>
  <acronym>MATHVTE</acronym>
  <official_title>Monotherapy Anticoagulation To Expedite Home Treatment of Venous</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter observational study, of the effectiveness of a standard of care&#xD;
      protocol implemented to enhance home treatment of VTE. Study population will be selected as&#xD;
      part of usual care as eligible for home treatment. Study personnel will travel to&#xD;
      participating institutions to qualify the sites, deliver a Powerpoint速 lecture to introduce&#xD;
      the protocol, meet and train site principal investigators, emergency physicians and research&#xD;
      personnel on the implementation of the protocol as part of usual clinical care, and data&#xD;
      collection methods for a quality assurance registry with plans to use the data collected in&#xD;
      this registry in future publications. Follow-up will be 30 days using medical records and/or&#xD;
      telephone interview to assess for primary outcomes of bleeding or VTE recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Actual">May 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of re-hospitalization visits for VTE recurrence or bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Re-hospitalization for &gt; 24 hours due to VTE recurrence or bleeding</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1300</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Apixaban for VTE</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban for VTE</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban as standard of care for VTE</description>
    <arm_group_label>Apixaban for VTE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban as standard of care for VTE</description>
    <arm_group_label>Rivaroxaban for VTE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Emergency department patients with new or recurrent VTE deemed low-risk by modified Hestia&#xD;
        or clinician discretion and sPESI (-).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be low risk, as defined by either A or B below:&#xD;
&#xD;
             A. The modified Hestia criteria:&#xD;
&#xD;
               -  Systolic blood pressure &gt; 100 mm Hg&#xD;
&#xD;
               -  No thrombolysis needed&#xD;
&#xD;
               -  No active bleeding&#xD;
&#xD;
               -  SaO2 &gt;94% while breathing room air&#xD;
&#xD;
               -  Not already anticoagulated&#xD;
&#xD;
               -  No more than two doses of IV narcotics in the emergency department&#xD;
&#xD;
               -  Other medical or social reasons to admit&#xD;
&#xD;
               -  Creatinine clearance &gt;30mL/min&#xD;
&#xD;
               -  Not pregnant, severe liver disease or heparin induced thrombocytopenia OR&#xD;
&#xD;
             B. The physician opinion that a patients' overall social and medical situation is&#xD;
             favorable for home treatment and the patient has a zero score on the simplified&#xD;
             pulmonary embolism severity index (sPESI).&#xD;
&#xD;
             All of the following must true:&#xD;
&#xD;
               -  Age &lt; 81 years&#xD;
&#xD;
               -  No history of cancer&#xD;
&#xD;
               -  No history of heart failure or chronic lung disease&#xD;
&#xD;
               -  Pulse &lt; 110 beats/min&#xD;
&#xD;
               -  SBP &gt; 99 mm Hg&#xD;
&#xD;
               -  O2 sat &gt;89%%&#xD;
&#xD;
             We have chosen either criteria because both have been found equal in terms of safety&#xD;
             for outpatient treatment of PE.6,22 Hestia includes implicit questions that most&#xD;
             emergency physicians would use as criteria for discharge (e.g., overall medical status&#xD;
             and social situation), whereas sPESI does not. For that reason, we have added the&#xD;
             additional gestalt assessment question about physician discretion.&#xD;
&#xD;
          2. Patients must be discharged in &lt;24 hours after triage in an ED visit with diagnosis of&#xD;
             VTE using objective criteria in the emergency department.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  VTE diagnosis while taking anticoagulants with evidence of compliance (e.g., physician&#xD;
             opinion that patient is taking a Eliquis速, Xarelto速 or Pradaxa速, low molecular weight&#xD;
             heparin injections or warfarin as prescribed for any condition)&#xD;
&#xD;
          -  Sensitivity or contraindication to use of apixaban&#xD;
&#xD;
          -  Troponin assay value, drawn as part of usual care and found to be positive, using&#xD;
             local standards&#xD;
&#xD;
          -  High risk for hemorrhage defined by a score&gt;1.5 using the method of Ruiz Gimenez.3&#xD;
             (Note that several criteria are already excluded by Hestia):&#xD;
&#xD;
        Recent major bleeding, 2 points Creatinine levels &gt;1.2 mg/dl, 1.5 points Anemia, 1.5 points&#xD;
        Cancer, 1 point Clinically overt PE, 1 point Age &gt;75 years, 1 point&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eskenazi Health System</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

